企業プロフィール
GeoVax Labs 株価・ニュース・カタリスト
- ティッカー:
- GOVX
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
0.32 USD (-3.56%)
終値
最終更新: 2026年10月1日
10.9M USD
時価総額
株価変動の要因
2026年10月1日 時点で GOVX は 3.56% 下落し、$0.3222 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Vaccine and Immunotherapy Company
GeoVax Labs develops vaccines and cancer immunotherapies using modified vaccinia Ankara vectors and gene-directed therapy. Its portfolio targets emerging infectious diseases and difficult-to-treat solid tumors.
GEO-MVA for Mpox and Smallpox
GEO-MVA is a live, non-replicating MVA vaccine being developed for protection against mpox and smallpox. The program is intended to support public-health preparedness and provide an alternative vaccine option for vulnerable populations.
Immunobridging Regulatory Strategy
Because efficacy trials against smallpox are not feasible, GeoVax plans to compare immune responses generated by GEO-MVA with those from an established vaccine. A successful immunobridging study could support regulatory submissions.
Gedeptin Cancer Gene Therapy
Gedeptin is a gene-directed enzyme prodrug therapy delivered into tumors. It is designed to convert an administered prodrug into an active anticancer agent locally and is being explored with checkpoint inhibition.
MVA Platform Capabilities
The company's MVA technology can deliver multiple antigens in a single vaccine and stimulate both antibody and T-cell responses. Government relationships and external manufacturing partners are important to development and stockpile opportunities.
今後のカタリスト
- Initiation of the pivotal GEO-MVA immunobridging study in the fourth quarter of 2026.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。